Session » Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis
-
Abstract Number: 2379
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
-
Abstract Number: 2380
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
-
Abstract Number: 2381
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
-
Abstract Number: 2382
Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
-
Abstract Number: 2383
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
-
Abstract Number: 2384
Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
-
Abstract Number: 2386
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
-
Abstract Number: 2388
Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis
-
Abstract Number: 2389
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
-
Abstract Number: 2390
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
-
Abstract Number: 2391
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
-
Abstract Number: 2392
Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?
-
Abstract Number: 2393
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
-
Abstract Number: 2394
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
-
Abstract Number: 2395
Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals
-
Abstract Number: 2396
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
-
Abstract Number: 2397
The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
-
Abstract Number: 2398
Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category
-
Abstract Number: 2400
Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population
-
Abstract Number: 2401
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
-
Abstract Number: 2402
Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study
-
Abstract Number: 2403
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
-
Abstract Number: 2404
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
-
Abstract Number: 2405
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
-
Abstract Number: 2406
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents